ClinicalTrials.gg
CompletedNCT00337662Updated Feb 17, 2010Results posted

Efficacy Study of Early Onset of Antipsychotic Drug Action in Schizophrenia

A Phase 4 interventional study of olanzapine and risperidone in Schizophrenia, Schizoaffective Disorder and Schizophreniform Disorder, sponsored by Eli Lilly and Company. Completed at 34 sites in 3 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2010-02-17.

Sponsored by Eli Lilly and Company · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
628
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 97 studies testing olanzapine in Schizophrenia — 2 open to participants now, 3 under way, 1 of them phase 3. Olanzapine · Schizophrenia.

Enrollment
8th of 94
628 · median 114
Started
2006
with 8 others
Phase 4
46 of 97
1 open now
Registered
40th of 97
by date
Lead sponsor
22 of 97
Eli Lilly and Company

Among the 97 studies testing olanzapine in Schizophrenia, this one is the 8th largest by enrollment of the 94 interventional ones that give a count, is one of 9 that started in 2006, is one of 46 in phase 4, and was the 40th registered.

Schizophrenia

3,571 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

2 of the 97 studies testing olanzapine in Schizophrenia are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About olanzapine

Olanzapine: first FDA approval 1996 (ZYPREXA), first EMA approval 1996. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 97 studies testing olanzapine in Schizophrenia, or all of them as a file.
02

Study summary

The current study has been designed to address the significance of early onset of response prospectively in patients treated with an atypical antipsychotic.

03

Conditions studied

  • Schizophrenia
  • Schizoaffective Disorder
  • Schizophreniform Disorder
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients must demonstrate acute psychopathologic severity criteria and be at least moderately ill.
  • Patients must have experienced an exacerbation of their illness within the previous 2 weeks.
  • Patients in whom a switch to another antipsychotic medication is acutely indicated.

Exclusion criteria

Exclusion Criteria:

  • Patients who are deemed nonresponsive to risperidone or olanzapine.
  • Patients who have been hospitalized for greater than 2 weeks immediately prior to Visit 1.
  • Patients having received olanzapine or risperidone in the past 30 days.
  • Treatment with clozapine within 1 year prior to Visit 1.
  • Diagnosis of substance-induced psychosis by Fourth Edition (DSM-IV) criteria within 7 days of Visit 1 (or at any time during the study), or confirmed on clinical grounds within 72 hours subsequent to Visit 1 (or at any time during the study).
  • A diagnosis of Parkinson's disease, dementia-related psychosis, or related disorders.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
628 participants (actual)

Study arms

  • Experimental
    1

    Olanzapine for Not Early Onset response (NEO) patients

    Drug: olanzapine

  • Active comparator
    2

    Risperidone for Not Early Onset response (NEO) patients

    Drug: risperidone

  • Active comparator
    3

    Risperidone for Early Onset response (EO) patients

    Drug: risperidone

Interventions

  • 10-20 milligrams (mg), oral, daily, 10 weeks.

    Also known as: LY170053, Zyprexa

  • 2-6 mg, oral, daily, for 10 weeks.

  • 2-6 mg, oral, daily, 10 weeks

06

What researchers measure

Primary outcomes

  1. Changes From Study Period II Baseline (Week 0) to Weeks 3, 4, 6, 8, and 12 in Positive and Negative Syndrome Scale (PANSS) Total Score in Early Onset Response and Not Early Onset Response-Risperidone Patients

    Assesses positive symptoms, negative symptoms, and general psychopathology specifically associated with schizophrenia. Scale consists of 30 items. Each item is rated on a scale from 1 (symptom not present) to 7 (symptoms extremely severe). Sum of 30 items is PANSS total score and ranges from 30 to 210. Change = time point - single-blind baseline (Week 0).

    Time frame: Weeks 0, 3, 4, 6, 8, 12

Secondary outcomes

  1. Changes From Study Period III Baseline (Week 2) to Weeks 3, 4, 6, 8, and 12 in Positive and Negative Syndrome Scale Total Score in Not Early Onset Response-Risperidone and Not Early Onset Response-Olanzapine Patients

    Assesses positive symptoms, negative symptoms, and general psychopathology specifically associated with schizophrenia. Scale consists of 30 items. Each item is rated on a scale from 1 (symptom not present) to 7 (symptoms extremely severe). Sum of 30 items is PANSS total score and ranges from 30 to 210. Change = time point - double-blind baseline (Week 2).

    Time frame: Weeks 2, 3, 4, 6, 8, 12

  2. The Number of Participants in the Early Onset (EO) and Not Early Onset-Risperidone (NEO-RIS) Groups Who Show a 20% or Greater Reduction in Positive and Negative Syndrome Scale (PANSS) Total Score

    The number of participants who experienced a 20% or greater reduction in their PANSS Total score during the 12 weeks they were on risperidone.

    Time frame: Week 0 to Week 12

  3. The Number of Participants in the Not Early Onset-Risperidone (NEO-RIS) and Not Early Onset-Olanzapine (NEO-OLZ) Groups Who Show a 20% or Greater Reduction in Positive and Negative Syndrome Scale (PANSS) Total Score

    The number of not early onset participants who experienced a 20% or greater reduction in PANSS Total Score at any time during the 12 weeks of combined Study Period II and Study Period III.

    Time frame: Week 0 to Week 12

  4. Number of Participants in the Early Onset and Not Early Onset-Risperidone Groups Who Show a 50% or Greater Reduction in Positive and Negative Syndrome Scale (PANSS) Total Score From Baseline or Meet 'a Priori' Specified Criteria for Remission

    'a priori' specified criteria for remission defined as a score of 3 (mild), 2 (minimal), or 1 (absent) on all of the following 8 PANSS items: delusions, conceptual disorganization, hallucinatory behavior, unusual thought content, mannerisms and posturing, blunted effect, passive/apathetic withdrawal, lack of spontaneity and flow of conversation.

    Time frame: Week 0 to Week 12

  5. Number of Participants in the Not Early Onset-Risperidone and Not Early Onset-Olanzapine Groups Who Show a 50% or Greater Reduction in Positive and Negative Syndrome Scale Total Score From Baseline or Meet 'a Priori' Specified Criteria for Remission

    'a priori' specified criteria for remission defined as a score of 3 (mild), 2 (minimal), or 1 (absent) on all of the following 8 PANSS items: delusions, conceptual disorganization, hallucinatory behavior, unusual thought content, mannerisms and posturing, blunted effect, passive/apathetic withdrawal, lack of spontaneity and flow of conversation.

    Time frame: Week 2 to Week 12

  6. Number of Participants With Psychiatric Hospitalizations in the Early Onset and Not Early Onset-Risperidone Groups

    Psychiatric Hospitalizations were measured by the Modified Schizophrenia Care and Assessment Program Health Questionnaire (SCAP-HQ) from which it could be determined the number of patients with a psychiatric episode that required an overnight stay in a hospital.

    Time frame: Week 2 to Week 12

  7. Vital Signs - Mean Change From Baseline to 10 Week Endpoint in Body Mass Index

    Body mass index is an estimate of body fat based on body weight divided by height squared. Change = Endpoint minus baseline.

    Time frame: Week 2 to Week 12

  8. Number of Participants With Treatment-Emergent Abnormal Fasting Laboratory Analytes Reported in >=2% of All Participants

    Number of participants who experienced abnormal fasting laboratory values at any time during Study Period III. Laboratory reference ranges are dependent on the patient's gender, origin, and age.

    Time frame: Week 2 to Week 12

  9. Mean Change From Baseline to 10 Week Endpoint in Extrapyramidal Symptoms as Measured by the Modified Simpson-Angus Scale

    Measures neuroleptic-induced parkinsonism. Total score consists of the sum of 10 items: 7 items (items 1, 3, 4, 7, 8, 9, 10) rated on a 4-point severity scale where 0=normal and 4=extreme, and 3 items (items 2, 5, 6) rated on a 2-point severity scale where 0=normal and 2=definitely abnormal/present. The total score ranges from 0 to 34.

    Time frame: Week 2 to Week 12

  10. Mean Change From Baseline to 10 Week Endpoint in Extrapyramidal Symptoms as Measured by the Barnes Akathisia Rating Scale - Total Score

    Evaluates akathisia associated with use of antipsychotic medications, includes objective and subjective component plus global impression rating for overall disorder. Components rated on scale of 0 to 3 for objective and subjective items and 0 to 5 for global clinical assessment, for total score of 0 (absence of akathisia) to 11 (severe akathisia).

    Time frame: Week 2 to Week 12

  11. Mean Change From Baseline to 10 Week Endpoint in Extrapyramidal Symptoms as Measured by the Abnormal Involuntary Movement Scale (AIMS)- Non-Global Total Score

    A 12-item instrument assesses observed abnormal movements in different parts of body. Ten items are scored in a 5-point scale (0 = none/normal, 4 = severe) which evaluates abnormal movements in three main anatomic areas (orofacial area, extremities, and trunk). Two items are yes/no questions regarding dentures. Total scores range from 0 to 42.

    Time frame: Week 2 to Week 12

  12. Vital Signs - Mean Change From Baseline to 10 Week Endpoint in Sitting Pulse Rate

    Changes from Study Period III baseline to endpoint in sitting pulse rate. Change = Endpoint minus baseline.

    Time frame: Week 2 and Week 12

  13. Vital Signs - Change From Baseline to 10 Week Endpoint in Standing Diastolic Blood Pressure

    Change from Study Period III baseline to endpoint in standing blood pressure. Change = Endpoint minus baseline.

    Time frame: Week 2 and Week 12

  14. Vital Signs - Change From Baseline to 10 Week Endpoint in Standing Mean Arterial Pressure

    Change from Study Period III baseline to endpoint in standing mean arterial pressure. Change = Endpoint minus baseline.

    Time frame: Week 2 and Week 12

  15. Vital Signs - Mean Change From Baseline to 10 Week Endpoint in Standing Pulse Rate

    Change from Study Period III baseline to endpoint in standing pulse rate. Change = Endpoint minus baseline.

    Time frame: Week 2 and Week 12

  16. Vital Signs - Mean Change From Baseline to 10 Week Endpoint in Standing Systolic Blood Pressure

    Change from Study Period III baseline to endpoint in standing systolic blood pressure. Change = Endpoint minus baseline.

    Time frame: Week 2 and Week 12

  17. Vital Signs - Mean Change From Baseline to 10 Week Endpoint in Body Weight

    Change from Study Period III baseline to endpoint in body weight. Change = Endpoint minus baseline.

    Time frame: Week 2 and Week 12

07

Results

Posted Aug 4, 2009

Participant flow

Study Period II
Participant flow — Study Period II
MilestoneNEO-OLZNEO-RISEO-RISRisperiodone Open-Label Lead-In
Started000628
Completed000522
Not completed000106
Withdrew: Lost to follow-up00035
Withdrew: Withdrawal by subject00020
Withdrew: Adverse event00016
Withdrew: Physician decision00013
Withdrew: Entry criteria not met0006
Withdrew: Protocol violation0006
Withdrew: Lack of efficacy0007
Withdrew: Sponsor decision0002
Withdrew: Parent/caregiver decision0001
Study Period III
Participant flow — Study Period III
MilestoneNEO-OLZNEO-RISEO-RISRisperiodone Open-Label Lead-In
Started1861921440
Completed1261341000
Not completed6058440
Withdrew: Lost to follow-up1416140
Withdrew: Withdrawal by subject1814120
Withdrew: Adverse event91080
Withdrew: Protocol violation3820
Withdrew: Physician decision6500
Withdrew: Entry criteria not met4130
Withdrew: Lack of efficacy4420
Withdrew: Parent/caregiver decision0020
Withdrew: Sponsor decision1010
Withdrew: Clinical relapse1000

Outcome measures

PrimaryChanges From Study Period II Baseline (Week 0) to Weeks 3, 4, 6, 8, and 12 in Positive and Negative Syndrome Scale (PANSS) Total Score in Early Onset Response and Not Early Onset Response-Risperidone Patients

Assesses positive symptoms, negative symptoms, and general psychopathology specifically associated with schizophrenia. Scale consists of 30 items. Each item is rated on a scale from 1 (symptom not present) to 7 (symptoms extremely severe). Sum of 30 items is PANSS total score and ranges from 30 to 210. Change = time point - single-blind baseline (Week 0).

Time frame:
Weeks 0, 3, 4, 6, 8, 12
Reported as:
Least squares mean · units on a scale
Changes From Study Period II Baseline (Week 0) to Weeks 3, 4, 6, 8, and 12 in Positive and Negative Syndrome Scale (PANSS) Total Score in Early Onset Response and Not Early Onset Response-Risperidone Patients
units on a scaleNEO-RISEO-RIS
Change from Week 0 to Week 3-11.90 ± 1.15-30.80 ± 1.23
Change from Week 0 to Week 4-14.81 ± 1.16-32.53 ± 1.24
Change from Week 0 to Week 6-16.23 ± 1.26-32.90 ± 1.36
Change from Week 0 to Week 8-18.10 ± 1.31-34.10 ± 1.43
Change from Week 0 to Week 12-18.62 ± 1.38-35.09 ± 1.50
Statistical analysis
  • NEO-RIS vs EO-RIS · Mixed Effects Model Repeated Measures · p = <0.001 (Between-group p-values for each baseline to post-baseline visit were the same, p\<0.001.)
SecondaryChanges From Study Period III Baseline (Week 2) to Weeks 3, 4, 6, 8, and 12 in Positive and Negative Syndrome Scale Total Score in Not Early Onset Response-Risperidone and Not Early Onset Response-Olanzapine Patients

Assesses positive symptoms, negative symptoms, and general psychopathology specifically associated with schizophrenia. Scale consists of 30 items. Each item is rated on a scale from 1 (symptom not present) to 7 (symptoms extremely severe). Sum of 30 items is PANSS total score and ranges from 30 to 210. Change = time point - double-blind baseline (Week 2).

Time frame:
Weeks 2, 3, 4, 6, 8, 12
Reported as:
Least squares mean · units on a scale
Changes From Study Period III Baseline (Week 2) to Weeks 3, 4, 6, 8, and 12 in Positive and Negative Syndrome Scale Total Score in Not Early Onset Response-Risperidone and Not Early Onset Response-Olanzapine Patients
units on a scaleNEO-RISNEO-OLZ
Change from Week 2 to Week 3-6.94 ± 0.82-5.85 ± 0.84
Change from Week 2 to Week 4-9.82 ± 0.86-9.67 ± 0.88
Change from Week 2 to Week 6-11.25 ± 0.98-13.06 ± 1.02
Change from Week 2 to Week 8-13.13 ± 1.00-14.73 ± 1.04
Change from Week 2 to Week 12-13.53 ± 1.13-17.02 ± 1.16
Statistical analysis
  • NEO-RIS vs NEO-OLZ · Mixed-Effects Model Repeated-Measures · p = 0.266 (Change from Week 2 to Week 3 p-value)
  • NEO-RIS vs NEO-OLZ · Mixed-Effects Model Repeated-Measures · p = 0.884 (Change from Week 2 to Week 4 p-value)
  • NEO-RIS vs NEO-OLZ · Mixed-Effects Model Repeated-Measures · p = 0.151 (Change from Week 2 to Week 6 p-value)
  • NEO-RIS vs NEO-OLZ · Mixed-Effects Model Repeated-Measures · p = 0.216 (Change from Week 2 to Week 8 p-value)
  • NEO-RIS vs NEO-OLZ · Mixed-Effects Model Repeated-Measures · p = 0.020 (Change from Week 2 to Week 12 p-value)
SecondaryThe Number of Participants in the Early Onset (EO) and Not Early Onset-Risperidone (NEO-RIS) Groups Who Show a 20% or Greater Reduction in Positive and Negative Syndrome Scale (PANSS) Total Score

The number of participants who experienced a 20% or greater reduction in their PANSS Total score during the 12 weeks they were on risperidone.

Time frame:
Week 0 to Week 12
Reported as:
Number · participants
The Number of Participants in the Early Onset (EO) and Not Early Onset-Risperidone (NEO-RIS) Groups Who Show a 20% or Greater Reduction in Positive and Negative Syndrome Scale (PANSS) Total Score
participantsNEO-RISEO-RIS
>=20% Reduction - Yes94119
>=20% Reduction - No9519
Statistical analysis
  • NEO-RIS vs EO-RIS · Fisher Exact · p = <0.001
SecondaryThe Number of Participants in the Not Early Onset-Risperidone (NEO-RIS) and Not Early Onset-Olanzapine (NEO-OLZ) Groups Who Show a 20% or Greater Reduction in Positive and Negative Syndrome Scale (PANSS) Total Score

The number of not early onset participants who experienced a 20% or greater reduction in PANSS Total Score at any time during the 12 weeks of combined Study Period II and Study Period III.

Time frame:
Week 0 to Week 12
Reported as:
Number · participants
The Number of Participants in the Not Early Onset-Risperidone (NEO-RIS) and Not Early Onset-Olanzapine (NEO-OLZ) Groups Who Show a 20% or Greater Reduction in Positive and Negative Syndrome Scale (PANSS) Total Score
participantsNEO-RISNEO-OLZ
>=20% Reduction - Yes9494
>=20% Reduction - No9585
Statistical analysis
  • NEO-RIS vs NEO-OLZ · Fisher Exact · p = 0.604
SecondaryNumber of Participants in the Early Onset and Not Early Onset-Risperidone Groups Who Show a 50% or Greater Reduction in Positive and Negative Syndrome Scale (PANSS) Total Score From Baseline or Meet 'a Priori' Specified Criteria for Remission

'a priori' specified criteria for remission defined as a score of 3 (mild), 2 (minimal), or 1 (absent) on all of the following 8 PANSS items: delusions, conceptual disorganization, hallucinatory behavior, unusual thought content, mannerisms and posturing, blunted effect, passive/apathetic withdrawal, lack of spontaneity and flow of conversation.

Time frame:
Week 0 to Week 12
Reported as:
Number · participants
Number of Participants in the Early Onset and Not Early Onset-Risperidone Groups Who Show a 50% or Greater Reduction in Positive and Negative Syndrome Scale (PANSS) Total Score From Baseline or Meet 'a Priori' Specified Criteria for Remission
participantsNEO-RISEO-RIS
>=50% Reduction - Yes6787
>=50% Reduction - No12251
Statistical analysis
  • NEO-RIS vs EO-RIS · Fisher Exact · p = <0.001
SecondaryNumber of Participants in the Not Early Onset-Risperidone and Not Early Onset-Olanzapine Groups Who Show a 50% or Greater Reduction in Positive and Negative Syndrome Scale Total Score From Baseline or Meet 'a Priori' Specified Criteria for Remission

'a priori' specified criteria for remission defined as a score of 3 (mild), 2 (minimal), or 1 (absent) on all of the following 8 PANSS items: delusions, conceptual disorganization, hallucinatory behavior, unusual thought content, mannerisms and posturing, blunted effect, passive/apathetic withdrawal, lack of spontaneity and flow of conversation.

Time frame:
Week 2 to Week 12
Reported as:
Number · participants
Number of Participants in the Not Early Onset-Risperidone and Not Early Onset-Olanzapine Groups Who Show a 50% or Greater Reduction in Positive and Negative Syndrome Scale Total Score From Baseline or Meet 'a Priori' Specified Criteria for Remission
participantsNEO-RISNEO-OLZ
>=50% Reduction - Yes6767
>=50% Reduction - No122112
Statistical analysis
  • NEO-RIS vs NEO-OLZ · Fisher Exact · p = 0.745
SecondaryNumber of Participants With Psychiatric Hospitalizations in the Early Onset and Not Early Onset-Risperidone Groups

Psychiatric Hospitalizations were measured by the Modified Schizophrenia Care and Assessment Program Health Questionnaire (SCAP-HQ) from which it could be determined the number of patients with a psychiatric episode that required an overnight stay in a hospital.

Time frame:
Week 2 to Week 12
Reported as:
Number · participants
Number of Participants With Psychiatric Hospitalizations in the Early Onset and Not Early Onset-Risperidone Groups
participantsNEO-RISEO-RIS
Required overnight stay in hospital: Yes910
Required overnight stay in hospital: No175127
Statistical analysis
  • NEO-RIS vs EO-RIS · Fisher Exact · p = 0.474
SecondaryVital Signs - Mean Change From Baseline to 10 Week Endpoint in Body Mass Index

Body mass index is an estimate of body fat based on body weight divided by height squared. Change = Endpoint minus baseline.

Time frame:
Week 2 to Week 12
Reported as:
Mean · kilogram per square meter
Vital Signs - Mean Change From Baseline to 10 Week Endpoint in Body Mass Index
kilogram per square meterNEO-OLZNEO-RISEO-RIS
Baseline29.97 ± 8.0331.05 ± 8.0431.13 ± 8.77
Change from Baseline0.63 ± 1.380.43 ± 1.450.10 ± 1.19
Statistical analysis
  • NEO-RIS vs EO-RIS · ANOVA · p = 0.034 (P-values (Change from Baseline) are based on Type III sums of squares from ANOVA model: change = group pooled investigator.)
  • NEO-OLZ vs NEO-RIS · ANOVA · p = 0.125 (P-values (Change from Baseline) are based on Type III sums of squares from ANOVA model: change = group pooled investigator.)
SecondaryNumber of Participants With Treatment-Emergent Abnormal Fasting Laboratory Analytes Reported in >=2% of All Participants

Number of participants who experienced abnormal fasting laboratory values at any time during Study Period III. Laboratory reference ranges are dependent on the patient's gender, origin, and age.

Time frame:
Week 2 to Week 12
Reported as:
Number · participants
Number of Participants With Treatment-Emergent Abnormal Fasting Laboratory Analytes Reported in >=2% of All Participants
participantsNEO-OLZNEO-RISEO-RIS
Low total bilirubin532
High creatine phosphokinase615
High creatinine243
High hemoglobin A1c672
Low sodium444
High prolactin787
Statistical analysis
  • NEO-OLZ vs NEO-RIS vs EO-RIS · Fisher Exact · p = >0.05 (All comparisons between EO-RIS and NEO-RIS and between NEO-RIS and NEO-OLZ had p-values greater than 0.05.)
SecondaryMean Change From Baseline to 10 Week Endpoint in Extrapyramidal Symptoms as Measured by the Modified Simpson-Angus Scale

Measures neuroleptic-induced parkinsonism. Total score consists of the sum of 10 items: 7 items (items 1, 3, 4, 7, 8, 9, 10) rated on a 4-point severity scale where 0=normal and 4=extreme, and 3 items (items 2, 5, 6) rated on a 2-point severity scale where 0=normal and 2=definitely abnormal/present. The total score ranges from 0 to 34.

Time frame:
Week 2 to Week 12
Reported as:
Mean · units on a scale
Mean Change From Baseline to 10 Week Endpoint in Extrapyramidal Symptoms as Measured by the Modified Simpson-Angus Scale
units on a scaleNEO-OLZNEO-RISEO-RIS
Mean Change From Baseline to 10 Week Endpoint in Extrapyramidal Symptoms as Measured by the Modified Simpson-Angus Scale-0.06 ± 0.27-0.03 ± 0.26-0.02 ± 0.16
Statistical analysis
  • NEO-RIS vs EO-RIS · ANOVA · p = 0.355p-value is from ANOVA with treatment and pooled investigator in the model.
  • NEO-OLZ vs NEO-RIS · ANOVA · p = 0.244p-value is from ANOVA with treatment and pooled investigator in the model.
SecondaryMean Change From Baseline to 10 Week Endpoint in Extrapyramidal Symptoms as Measured by the Barnes Akathisia Rating Scale - Total Score

Evaluates akathisia associated with use of antipsychotic medications, includes objective and subjective component plus global impression rating for overall disorder. Components rated on scale of 0 to 3 for objective and subjective items and 0 to 5 for global clinical assessment, for total score of 0 (absence of akathisia) to 11 (severe akathisia).

Time frame:
Week 2 to Week 12
Reported as:
Mean · units on a scale
Mean Change From Baseline to 10 Week Endpoint in Extrapyramidal Symptoms as Measured by the Barnes Akathisia Rating Scale - Total Score
units on a scaleNEO-OLZNEO-RISEO-RIS
Mean Change From Baseline to 10 Week Endpoint in Extrapyramidal Symptoms as Measured by the Barnes Akathisia Rating Scale - Total Score-0.31 ± 1.99-0.13 ± 2.04-0.24 ± 1.38
Statistical analysis
  • NEO-RIS vs EO-RIS · ANOVA · p = 0.998P-value is from ANOVA with treatment and pooled investigator in the model.
  • NEO-OLZ vs NEO-RIS · ANOVA · p = 0.505P-value is from ANOVA with treatment and pooled investigator in the model.
SecondaryMean Change From Baseline to 10 Week Endpoint in Extrapyramidal Symptoms as Measured by the Abnormal Involuntary Movement Scale (AIMS)- Non-Global Total Score

A 12-item instrument assesses observed abnormal movements in different parts of body. Ten items are scored in a 5-point scale (0 = none/normal, 4 = severe) which evaluates abnormal movements in three main anatomic areas (orofacial area, extremities, and trunk). Two items are yes/no questions regarding dentures. Total scores range from 0 to 42.

Time frame:
Week 2 to Week 12
Reported as:
Mean · units on a scale
Mean Change From Baseline to 10 Week Endpoint in Extrapyramidal Symptoms as Measured by the Abnormal Involuntary Movement Scale (AIMS)- Non-Global Total Score
units on a scaleNEO-OLZNEO-RISEO-RIS
Mean Change From Baseline to 10 Week Endpoint in Extrapyramidal Symptoms as Measured by the Abnormal Involuntary Movement Scale (AIMS)- Non-Global Total Score-0.38 ± 1.730.11 ± 2.07-0.16 ± 1.27
Statistical analysis
  • NEO-RIS vs EO-RIS · ANOVA · p = 0.266P-value is from ANOVA with treatment and pooled investigator in the model.
  • NEO-OLZ vs NEO-RIS · ANOVA · p = 0.015P-value is from ANOVA with treatment and pooled investigator in the model.
SecondaryVital Signs - Mean Change From Baseline to 10 Week Endpoint in Sitting Pulse Rate

Changes from Study Period III baseline to endpoint in sitting pulse rate. Change = Endpoint minus baseline.

Time frame:
Week 2 and Week 12
Reported as:
Mean · beats per minute
Vital Signs - Mean Change From Baseline to 10 Week Endpoint in Sitting Pulse Rate
beats per minuteNEO-OLZNEO-RISEO-RIS
Baseline80.49 ± 11.5780.84 ± 12.0677.90 ± 11.02
Change from Baseline-0.98 ± 11.81-2.52 ± 11.50-0.94 ± 12.82
Statistical analysis
  • NEO-RIS vs EO-RIS · ANOVA · p = 0.140 (P-values (Change from Baseline) are based on Type III sums of squares from ANOVA model: change = group pooled investigator.)
  • NEO-OLZ vs NEO-RIS · ANOVA · p = 0.181 (P-values (Change from Baseline) are based on Type III sums of squares from ANOVA model: change = group pooled investigator.)
SecondaryVital Signs - Change From Baseline to 10 Week Endpoint in Standing Diastolic Blood Pressure

Change from Study Period III baseline to endpoint in standing blood pressure. Change = Endpoint minus baseline.

Time frame:
Week 2 and Week 12
Reported as:
Mean · mm Hg
Vital Signs - Change From Baseline to 10 Week Endpoint in Standing Diastolic Blood Pressure
mm HgNEO-OLZNEO-RISEO-RIS
Baseline78.69 ± 10.0178.57 ± 10.6880.29 ± 10.65
Change from Baseline1.01 ± 10.79-0.20 ± 9.96-1.73 ± 8.92
Statistical analysis
  • NEO-RIS vs EO-RIS · ANOVA · p = 0.254 (P-values (Change from Baseline) are based on Type III sums of squares from ANOVA model: change = group pooled investigator.)
  • NEO-OLZ vs NEO-RIS · ANOVA · p = 0.299P-values (Change from Baseline) are based on Type III sums of squares from ANOVA model: change = group pooled investigator.
SecondaryVital Signs - Change From Baseline to 10 Week Endpoint in Standing Mean Arterial Pressure

Change from Study Period III baseline to endpoint in standing mean arterial pressure. Change = Endpoint minus baseline.

Time frame:
Week 2 and Week 12
Reported as:
Mean · mm Hg
Vital Signs - Change From Baseline to 10 Week Endpoint in Standing Mean Arterial Pressure
mm HgNEO-OLZNEO-RISEO-RIS
Baseline93.53 ± 10.2493.81 ± 11.4294.60 ± 10.67
Change from Baseline0.68 ± 9.58-0.58 ± 10.12-1.94 ± 8.13
Statistical analysis
  • NEO-RIS vs EO-RIS · ANOVA · p = 0.291 (P-values (Change from Baseline) are based on Type III sums of squares from ANOVA model: change = group pooled investigator.)
  • NEO-OLZ vs NEO-RIS · ANOVA · p = 0.259 (P-values (Change from Baseline) are based on Type III sums of squares from ANOVA model: change = group pooled investigator.)
SecondaryVital Signs - Mean Change From Baseline to 10 Week Endpoint in Standing Pulse Rate

Change from Study Period III baseline to endpoint in standing pulse rate. Change = Endpoint minus baseline.

Time frame:
Week 2 and Week 12
Reported as:
Mean · beats per minute
Vital Signs - Mean Change From Baseline to 10 Week Endpoint in Standing Pulse Rate
beats per minuteNEO-OLZNEO-RISEO-RIS
Baseline85.57 ± 12.8385.32 ± 13.5482.39 ± 11.46
Change from Baseline-1.13 ± 14.20-2.05 ± 13.21-0.56 ± 12.40
Statistical analysis
  • NEO-RIS vs EO-RIS · ANOVA · p = 0.209 (P-values (Change from Baseline) are based on Type III sums of squares from ANOVA model: change = group pooled investigator.)
  • NEO-OLZ vs NEO-RIS · ANOVA · p = 0.411 (P-values (Change from Baseline) are based on Type III sums of squares from ANOVA model: change = group pooled investigator.)
SecondaryVital Signs - Mean Change From Baseline to 10 Week Endpoint in Standing Systolic Blood Pressure

Change from Study Period III baseline to endpoint in standing systolic blood pressure. Change = Endpoint minus baseline.

Time frame:
Week 2 and Week 12
Reported as:
Mean · mm Hg
Vital Signs - Mean Change From Baseline to 10 Week Endpoint in Standing Systolic Blood Pressure
mm HgNEO-OLZNEO-RISEO-RIS
Baseline123.20 ± 14.02124.30 ± 16.23123.20 ± 13.63
Change from Baseline0.01 ± 12.90-1.35 ± 14.22-2.36 ± 10.78
Statistical analysis
  • NEO-RIS vs EO-RIS · ANOVA · p = 0.544 (P-values (Change from Baseline) are based on Type III sums of squares from ANOVA model: change = group pooled investigator.)
  • NEO-OLZ vs NEO-RIS · ANOVA · p = 0.386 (P-values (Change from Baseline) are based on Type III sums of squares from ANOVA model: change = group pooled investigator.)
SecondaryVital Signs - Mean Change From Baseline to 10 Week Endpoint in Body Weight

Change from Study Period III baseline to endpoint in body weight. Change = Endpoint minus baseline.

Time frame:
Week 2 and Week 12
Reported as:
Mean · kilograms
Vital Signs - Mean Change From Baseline to 10 Week Endpoint in Body Weight
kilogramsNEO-OLZNEO-RISEO-RIS
Baseline88.28 ± 23.5290.25 ± 22.8190.67 ± 25.39
Change from Baseline1.85 ± 3.971.29 ± 4.250.30 ± 3.26
Statistical analysis
  • NEO-RIS vs EO-RIS · ANOVA · p = 0.026 (P-values (Change from Baseline) are based on Type III sums of squares from ANOVA model: change = group pooled investigator.)
  • NEO-OLZ vs NEO-RIS · ANOVA · p = 0.143 (P-values (Change from Baseline) are based on Type III sums of squares from ANOVA model: change = group pooled investigator.)

Adverse events

Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
NEO-OLZ—19/186 (10.2%)—
NEO-RIS—12/192 (6.3%)—
EO-RIS—14/144 (9.7%)—
Most frequent serious events
Showing 10 of 26
Most frequent serious events
EventNEO-OLZNEO-RISEO-RIS
SchizophreniaPsychiatric disorders4/1861/1925/144
Suicidal ideationPsychiatric disorders4/1862/1924/144
Psychotic disorderPsychiatric disorders3/1862/1920/144
Schizoaffective disorderPsychiatric disorders3/1861/1920/144
Schizophrenia, paranoid typePsychiatric disorders1/1860/1922/144
PneumoniaInfections and infestations0/1861/1921/144
DysarthriaNervous system disorders0/1860/1921/144
Loss of consciousnessNervous system disorders0/1860/1921/144
AgitationPsychiatric disorders0/1860/1921/144
AnxietyPsychiatric disorders0/1860/1921/144
Most frequent other events
Showing 10 of 28
Most frequent other events
EventNEO-OLZNEO-RISEO-RIS
Weight increasedInvestigations20/18610/1924/144
LethargyNervous system disorders2/1863/19212/144
InsomniaPsychiatric disorders7/18616/1924/144
SedationNervous system disorders12/18611/1925/144
SomnolenceNervous system disorders5/18611/1926/144
DiarrhoeaGastrointestinal disorders2/18610/1924/144
HeadacheNervous system disorders9/1868/1927/144
AnxietyPsychiatric disorders8/1868/1927/144
Increased appetiteMetabolism and nutrition disorders5/1869/1923/144
Musculoskeletal stiffnessMusculoskeletal and connective tissue disorders1/1862/1926/144

Baseline characteristics

Age Continuous
Age Continuous(years)NEO-OLZNEO-RISEO-RISTotal
Mean41.84 ± 10.9241.87 ± 11.3441.83 ± 10.8841.85 ± 11.04
Sex: Female, Male
Sex: Female, Male(Participants)NEO-OLZNEO-RISEO-RISTotal
Female667658200
Male12011686322
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)NEO-OLZNEO-RISEO-RISTotal
American Indian or Alaska Native1214
Asian3003
Black or African American889254234
White808074234
Hispanic14181547
Region of Enrollment
Region of Enrollment(participants)NEO-OLZNEO-RISEO-RISTotal
United States173176130479
Argentina45918
Russian Federation911525
Diagnosis
Diagnosis(participants)NEO-OLZNEO-RISEO-RISTotal
Schizophrenia/Schizophreniform Disorder140144114398
Schizoaffective Bipolar Disorder31252177
Schizoaffective Depression1523947
Abnormal Involuntary Movement Scale - Non-Global Total Score
Abnormal Involuntary Movement Scale - Non-Global Total Score(units on a scale)NEO-OLZNEO-RISEO-RISTotal
Mean0.67 ± 1.820.49 ± 1.480.44 ± 1.380.54 ± 1.58
Barnes Akathisia Rating Scale Total Score
Barnes Akathisia Rating Scale Total Score(units on a scale)NEO-OLZNEO-RISEO-RISTotal
Mean0.80 ± 1.810.95 ± 1.970.54 ± 1.640.78 ± 1.83
Modified Simpson-Angus Scale
Modified Simpson-Angus Scale(units on a scale)NEO-OLZNEO-RISEO-RISTotal
Mean0.12 ± 0.290.14 ± 0.290.13 ± 0.820.13 ± 0.50

4 further baseline measures are reported on the registry.

08

Study locations

34 sites
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Little Rock, Arkansas 72201, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Escondido, California 92025, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Garden Grove, California 92845, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Glendale, California 91206, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    National City, California 91950, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Orange, California 92868, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    San Diego, California 92123, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Santa Ana, California 92701, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Washington, District of Columbia 20016, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Fort Lauderdale, Florida 33319, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Hialeah, Florida 33016, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Chicago, Illinois 60640, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Paducah, Kentucky 42003, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Lake Charles, Louisiana 70601, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Boston, Massachusetts 02118, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Jackson, Mississippi 39216, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Kansas City, Missouri 64108, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Omaha, Nebraska 68133, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Clementon, New Jersey 08021, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Cedarhurst, New York 11516, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Olean, New York 14760, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Staten Island, New York 10312, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Toledo, Ohio 43623, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Philadelphia, Pennsylvania 19131, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Rapid City, South Dakota 57701, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Memphis, Tennessee 38117, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Austin, Texas 78754, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Arlington, Virginia 22201, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Portsmouth, Virginia 23703, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Richmond, Virginia 23298, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Kirkland, Washington 98033, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Buenos Aires, C1062ABF, Argentina
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Khotkovo, 127025, Russian Federation
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Moscow, 115522, Russian Federation
09

References and documents

Publications

  • Chen L, Phillips G, Johnston J, Kinon BJ, Ascher-Svanum H, Kollack-Walker S, Succop P, Naber D. The relationship, structure and profiles of schizophrenia measurements: a post-hoc analysis of the baseline measures from a randomized clinical trial. BMC Psychiatry. 2011 Dec 28;11:203. doi: 10.1186/1471-244X-11-203. PubMed 22204569 ↗
  • Fijal BA, Stauffer VL, Kinon BJ, Conley RR, Hoffmann VP, Witte MM, Zhao F, Houston JP. Analysis of gene variants previously associated with iloperidone response in patients with schizophrenia who are treated with risperidone. J Clin Psychiatry. 2012 Mar;73(3):367-71. doi: 10.4088/JCP.10m06507. Epub 2011 Jul 12. PubMed 21813073 ↗
  • Ascher-Svanum H, Nyhuis AW, Stauffer V, Kinon BJ, Faries DE, Phillips GA, Schuh K, Awad AG, Keefe R, Naber D. Reasons for discontinuation and continuation of antipsychotics in the treatment of schizophrenia from patient and clinician perspectives. Curr Med Res Opin. 2010 Oct;26(10):2403-10. doi: 10.1185/03007995.2010.515900. PubMed 20812791 ↗
  • Kinon BJ, Chen L, Ascher-Svanum H, Stauffer VL, Kollack-Walker S, Zhou W, Kapur S, Kane JM. Early response to antipsychotic drug therapy as a clinical marker of subsequent response in the treatment of schizophrenia. Neuropsychopharmacology. 2010 Jan;35(2):581-90. doi: 10.1038/npp.2009.164. PubMed 19890258 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2006, a primary completion of Dec 2007 and a completion of Dec 2007. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2009, 1 year 8 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 14, 2006
First posted
Jun 16, 2006
Start
May 2006
Primary completionActual
Dec 2007
CompletionActual
Dec 2007
Results first posted
Aug 4, 2009
Last update
Feb 17, 2010
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 17, 2010, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00337662
First posted
Jun 16, 2006
Start date
May 2006
Primary completion
Dec 2007
Completion
Dec 2007
Results posted
Aug 4, 2009
Last update
Feb 17, 2010

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2010. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Olanzapine

Start the discussion